Boston Scientific Expands Medical Device R&D in Ireland With €75 Million Investment
GALWAY, Ireland — Boston Scientific will invest €75 million to expand research and development capabilities at its Galway facility, strengthening the site's role in developing next-generation cardiovascular and medical technologies.
The project includes new purpose-built laboratories designed to support the design, development and testing of medical devices across structural heart, cardiovascular and endoscopy programs, as well as emerging therapies for heart failure and renal denervation.
The Galway operation plays a significant role in Boston Scientific's global manufacturing network, which produces more than 30 million medical devices annually as part of the company's Irish operations. Products manufactured there include drug-coated devices, vascular balloons, heart stents and esophageal stents.
"We are seeing strong momentum across our cardiovascular business, and this investment reflects the important role the Galway site plays in that progress," said Lance Bates, executive vice president and president of Interventional Cardiology and Vascular Therapies at Boston Scientific. "The local team is delivering complex, highly collaborative work that is advancing meaningful innovation for patients."
Boston Scientific employs more than 7,000 people across facilities in Galway, Cork and Clonmel. The expansion is supported by the Irish government through IDA Ireland.
The company said the additional R&D capacity is intended to accelerate development of future medical technologies while supporting collaboration between engineering, product development and manufacturing teams.
Looking for quick answers on assembly and manufacturing topics? Try Ask ASM, our new smart AI search tool. Ask ASM
Looking for a reprint of this article?
From high-res PDFs to custom plaques, order your copy today!
